Kyntra Bio controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2021
Roxadustat data manipulation controversy
FibroGen acknowledged that analyses submitted to the FDA had been altered in a manner that made roxadustat appear safer and more effective. The disclosure triggered regulatory scrutiny, investor lawsuits, and rejection of the United States application.